Treatment and prevention of atrial fibrillation and flutter: new approaches and unsolved questions

Abstract

The article highlights the modern understanding of etiology, epidemiology and pathogenesis of atrial fibrillation and flutter and their global burden as the most frequent form of supraventricular sustained tachyarrhythmia. The recent international and Russian national clinical guidelines on the treatment and prevention of atrial fibrillation are briefly discussed. The new antiarrhythmic drugs, presented in recent guidelines are also highlighted. The authors analyze their own experience in the treatment of paroxysmal atrial fibrillation with IC class drugs (propafenone) at the prehospital stage.